CoChat

OPRM1 Asn40Asp Predicts Response to Naltrexone Treatment: A Haplotype‐Based Approach

Open access
Oroszi, Gabor, Anton, Raymond F., O’Malley, Stephanie, Swift, Robert, Pettinati, Helen, Couper, David, Yuan, Qiaoping, Goldman, David · 2009 · Alcoholism: Clinical and Experimental Research
Cited by 84

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Background: Individualized pharmacotherapy requires identification of genetic variants predictive of treatment response. In OPRM1, Asn40Asp has been reported to be predictive of response to naltrexone treatment. Nevertheless, the in vitro function of the polymorphism remains elusive and over 300 OPRM1 sequence variants have been identified to date. Therefore we used a haplotype‐based approach to capture information of other genetic variants that might predict treatment response to naltrexone in the COMBINE Study. Methods: 5′ nuclease genotyping assays (TaqMan®) were applied for 10 SNPs. Five‐locus haplotypes in 2 OPRM1 haplotype blocks were assigned to Caucasian participants. The relationship of the haplotypes to medication reflected by “good clinical outcome” was analyzed in 306 Caucasians treated without Combined Behavioral Intervention and with either naltrexone or placebo. Results: A significant haplotype by medication interaction (p = 0.03) was found in OPRM1 block 1. Naltrexone‐treated alcoholics with haplotype AGCCC, the single haplotype carrying the Asp40 allele had the highest percent of good clinical outcome. When interaction of genotypes at each of the 5 loci comprising block 1 with medication was examined, only the Asn40/Asp40 and Asp40/Asp40 genotypes were found to significantly interact with naltrexone treatment. No haplotype by medication interaction was documented in OPRM1 block 2. Conclusions: Our haplotype‐based approach confirms that the single OPRM1 locus predictive of response to naltrexone treatment is Asn40Asp in exon 1. A substantial contribution of any other OPRM1 genetic variant to interindividual variations in response to naltrexone treatment (at least in terms of good clinical outcome) is not supported by our findings.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1530-0277.2008.00846.x

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 84

Metadata

Authors
Oroszi, G., Anton, R. F., O’Malley, S., Swift, R., Pettinati, H., Couper, D., Yuan, Q., & Goldman, D.
Venue
Alcoholism: Clinical and Experimental Research
Publisher
Wiley
Published
2009-02-19
Volume
33
Issue
3
Pages
383-393
ISSN
  • 0145-6008 (ISSN-L)
  • 1530-0277
OpenAlex
W2103303496
Cited by
84
References
8
FWCI
5.45
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: OPRM1 Asn40Asp Predicts Response to Naltrexone Treatment: A Haplotype‐Based Approach. https://app.cochat.ai/papers/10.1111/j.1530-0277.2008.00846.x
The paper
Oroszi, G., Anton, R. F., O’Malley, S., Swift, R., Pettinati, H., Couper, D., Yuan, Q., & Goldman, D. (2009). OPRM1 Asn40Asp Predicts Response to Naltrexone Treatment: A Haplotype‐Based Approach. Alcoholism: Clinical and Experimental Research. https://doi.org/10.1111/j.1530-0277.2008.00846.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.